News

Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed. 

As Fido and Fluffy were spoiled more

The iShares Biotechnology ETF (NASDAQ: IBB) has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible

Tax software may not be the most glamorous business; as of today, no company in that industry has launched a virtual reality headset. However, if you’re scouting for a company with solid

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and

Pfizer Inc. (NYSE: PFE) released the results of a peer review study that sent shares up more than 5%. The study evaluated the company’s GLP-1 receptor agonist, danuglipron. The compound aimed to

Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon

Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report. 

Net income of $3.05 a

On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel

Beam Global Inc. (NASDAQ: BEEM) is emerging as a standout in the electric vehicle (EV) infrastructure space. As the EV movement continues to spread as more EVs get on the road, EV charging

Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A

Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne

Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.

Net income tumbled by 12% to $10.09 a

Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.

On April 19th, a

Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW